Evidence map›Paper›PMID 36727674›Full record

ArticleHepatology (Baltimore, Md.)2023

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

Mary E Rinella, Brent A Neuschwander-Tetri, Mohammad Shadab Siddiqui, Manal F Abdelmalek, Stephen Caldwell, Diana Barb, David E Kleiner, Rohit Loomba

6 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hepatology (Baltimore, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 1,427 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,427citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06121999 nacompletednot on this map

13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatosis (MASH) in Adults: A Randomized Control Trial

TypeinterventionalSponsorGrand Valley State UniversityRan2023 to 2024Enrolled24ConditionsMetabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)ArmsStandard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
NCT06334666 naenrolling by invitationnot on this mapstarted 2024, after this paper: background citation

The Efficacy of Pedometer-motivated Physical Activity for the Management of Patients With Metabolic-associated Steatotic Liver Disease: a Randomized-controlled Trial

TypeinterventionalSponsorMahidol UniversityRan2024 to 2026Enrolled86ConditionsDaily Step Count, MASLD, BMI, Metabolic SyndromeArmsEncourage using pedometer
NCT06676813 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis(NASH), A Randomized Controlled Trial. FAST Trial"

TypeinterventionalSponsorInstitute of Liver and Biliary Sciences, IndiaRan2024 to 2025Enrolled72ConditionsNon Alcoholic SteatohepatitisArmsAlternate day fasting
NCT06826807 naenrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Hepatic Elastography-Enhanced Lifestyle Modification in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized Controlled Trial

TypeinterventionalSponsorMahidol UniversityRan2025 to 2027Enrolled92ConditionsTransient Elastography, MASLD, BMI, Metabolic SyndromeArmsRegular monitoring with transient elastography
NCT07025980 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters in Patients With Metabolic Associated Steatotic Liver Disease

TypeinterventionalSponsorEva CubricRan2025 to 2029Enrolled114ConditionsMASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Diabetes Mellitus, Hypertension, HyperlipidaemiaArmsThe test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS, Placebo Drug
NCT07566299 completednot on this map

Early GLP-1 Receptor Agonist and SGLT2 Inhibitor Add-On Strategies in Adults With Obesity, Type 2 Diabetes, Cardiovascular-Kidney-Metabolic Syndrome Stage 2-3, and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Target Trial Emulation

TypeobservationalSponsorChung Shan Medical UniversityRan2017 to 2026Enrolled118,805ConditionsObesity Type 2 Diabetes Mellitus, Cardiovascular-kidney-metabolic Syndrome, Metabolic Dysfunction-Associated Steatotic Liver Disease
3 · Its place in the literature

Who cites it

1,427 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. [Construction norms for the tiered diagnosis and treatment and standardized management center of metabolic-associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. LncRNAiScience · 2026
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

1,367 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Mary E RinellaUniversity of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-0620-9705
Brent A Neuschwander-TetriSaint Louis University School of Medicine, Saint Louis, Missouri, USA.ORCID 0000-0002-8520-7398
Mohammad Shadab SiddiquiVirginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Manal F AbdelmalekMayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5001-8618
Stephen CaldwellSchool of Medicine, University of Virginia, Charlottesville, Virginia, USA.ORCID 0000-0003-1323-4191
Diana BarbUniversity of Florida College of Medicine, Gainesville, Florida, USA.ORCID 0000-0001-5208-6828
David E KleinerNational Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-3442-4453
Rohit LoombaUniversity of California, San Diego, San Diego, California, USA.ORCID 0000-0002-4845-9991

Funding

Postmortem PathologyZICBC010685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KLEINER, DAVID ERWIN · 2009 to 2025
$14.3M
Intramural NIH HHS ZIC BC010685
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Non-alcoholic Fatty Liver DiseaseDisease ProgressionHumansLiverLiver Cirrhosis

Identifiers

PMID36727674
PMCPMC10735173

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.